According to our recent payer coverage analysis for multiple myeloma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Topics: Market Access, Branding & Marketing, Specialty, Payer
In a move that one expert says Medicaid plans will be watching closely, Magellan Health and the drug manufacturer Otsuka America Pharmaceutical, Inc. said in August that they will work together to allow "select regional provider networks" contracted through Magellan to opt into a program involving the Abilify MyCite system, AIS Health reported.
Abilify (aripiprazole) treats schizophrenia and other mental illnesses. The MyCite system comprises Abilify tablets embedded with sensors; patches that detect and record the date and time of the pill's ingestion as well as physiological data like activity level; an app that lets patients review their data and enter additional information; and a web-based dashboard that lets providers and caregivers display and track a patient's drug ingestion patterns over time.
Topics: Specialty, Market Access, Payer
The 15th of October turned into a day of dueling proposals on the best way for pharmaceutical manufacturers to provide consumers with more information on medication prices. America’s Health Insurance Plans (AHIP) tells AIS Health that it sees merit in the federal government’s approach, while the pharma industry’s plan falls short.
It began with a pre-emptive strike in the morning when the Pharmaceutical Research and Manufacturers Association of America (PhRMA), stressing its commitment to price transparency, issued a press release.
Topics: Industry Trends, Specialty, Provider
According to our recent payer coverage analysis for chronic lymphocyctic leukemia (CLL) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Topics: Market Access, Branding & Marketing, Specialty, Payer
In an effort to pressure drug manufacturers to temper their launch prices for new drugs, CVS Health Corp. is rolling out a program in which drugs that have a price exceeding a certain cost-effectiveness threshold will be excluded from coverage, AIS Health reported.
CVS will let clients refuse to cover drugs that have a price tag of more than $100,000 per quality-adjusted life year (QALY), provided they are not designated as "breakthrough" therapies by the FDA.
Topics: Payer, Specialty, Industry Trends, Data & Analytics, Provider
At the annual Medicaid Health Plans of America conference, Express Scripts Holding Co. Senior Vice President and Chief Medical Officer Steve Miller, M.D., had a simple message for health plan leaders: "You have to think long term if you're going to have better outcomes," AIS Health reported.
One area in which Medicaid is not heeding that call, Miller said, is how it approaches treating and preventing HIV.
Topics: Industry Trends, Payer, Specialty, Provider
If the Trump administration gets its way, Medicare Part D plan sponsors may at some point be on the hook for a greater share of costs once beneficiaries reach the catastrophic phase of coverage for prescription drugs. While America's Health Insurance Plans (AHIP) is opposed to the idea, experts tell AIS Health that the time may be ripe for such a change.
Beneficiaries enter the catastrophic coverage phase when, as of 2018, their "true out-of-pocket costs" exceed $5,000. Once in that phase, beneficiaries pay no more than 5% of the total cost for their drugs, while the federal government pays 80% and the Part D plan pays 15%.
Topics: Industry Trends, Payer, Specialty, Provider
According to our recent payer coverage analysis for hypertension treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Topics: Market Access, Branding & Marketing, Specialty, Payer
The autoimmune therapy class boasts one of the broadest arrays of options within specialty drug classes. And while many physicians in general may tend to prescribe older medications that they have more familiarity with, a recent study shows that this may not necessarily be the case within this therapeutic class, AIS Health reported. The study, led by AllianceRx Walgreens Prime, found that among 5,547 analyzed psoriasis patients, providers may be comfortable with prescribing a newer type of autoimmune biologic as a first-line treatment.
The study assessed the use of two third-generation biologics, Novartis Pharmaceuticals Corp.’s Cosentyx (secukinumab) and Eli Lilly and Co.’s Taltz (ixekizumab), in the treatment of psoriasis. The FDA approved Cosentyx in January 2015, with Taltz’s approval coming about a year later, in March 2016.
Topics: Industry Trends, Market Access, Provider, Specialty
This June, the FDA approved Epidiolex (cannabidiol), the first-ever agency-approved treatment that contains a purified drug substance derived from marijuana, AIS Health reported. The oral solution, produced by GW Pharmaceuticals plc, is indicated for the treatment of seizures associated with two rare forms of childhood-onset epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome, for patients ages two and older.
The average gross price for Epidiolex will be $32,500 per year, Julian Gangolli, North America president of GW Pharmaceuticals, said during the company's Aug. 7 earnings call.
Topics: Specialty, Market Access, Payer
